Premium
Adjuvant chemohormonal therapy of high risk prostate carcinoma
Author(s) -
Bagley Charles M.,
Lane Robert F.,
Blasko John C.,
Grimm Peter D.,
Ragde Haakon,
Cobb Oliver E.,
Rowbotham Ronald K.
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10527
Subject(s) - medicine , radiation therapy , vinblastine , prostate cancer , chemotherapy , prostate specific antigen , oncology , hormonal therapy , cancer , carcinoma , randomized controlled trial , prostate , surgery , urology , gynecology
BACKGROUND Patients with T 3 and/or N 1 prostate carcinoma have poor cure rates. The authors sought to improve the relapse free, cancer specific survival of these patients by adding chemohormonal therapy to radiation. METHODS Twenty five men with clinical Stage III positive seminal vesicles or positive nodes received six courses of vinblastine, doxorubicin, and mitomycin with simultaneous radiation and permanent androgen deprivation. Prostate specific antigen (PSA) testing was the sole criterion for relapse. Median followup was 10.5 years. RESULTS Treatment was well tolerated. Patients received 91‐95% of each drug and all planned radiation. At 10 years the cumulative relapse free rate determined by continuously undetectable PSA levels was 73%, and the cumulative cancer specific survival was 81%. Of node‐positive patients, 82% were relapse‐free at 10 years. CONCLUSIONS The addition of chemotherapy to hormonal and radiation therapy is feasible and is accepted by most men when they are openly informed of their prognosis with conventional therapy. Results in the current small series appear excellent and may be superior to radiation plus hormones alone. Larger randomized studies are warranted. Cancer 2002; 94:2728–32. © 2002 American Cancer Society. DOI 10.1002/cncr.10527